Xeris Biopharma shares surge 15.85% premarket after reporting record $85.8M Q4 revenue and $375M–$390M 2026 guidance.

Xeris Biopharma (XERS) surged 15.85% in premarket trading following the release of record fourth-quarter and full-year 2025 financial results, including $86 million in Q4 revenue and $292 million in annual revenue, alongside 2026 guidance of $375–$390 million. The company reported a 100% year-over-year increase in Recorlev revenue and a $11.1 million net profit for Q4, contrasting with a $5.1 million loss in the prior-year period. Strong product demand, favorable pricing for Gvoke, and adjusted EBITDA growth of $25.1 million in Q4 underscored operational improvements. Management highlighted "transformational" 2025 performance and emphasized continued revenue growth, positioning the firm as self-funding and sustainable. The premarket rally reflects investor optimism about the company’s profitability, market expansion, and pipeline progress, particularly for XP-8121, ahead of its Phase 3 trial.